僵直性脊椎炎治疗市场规模、份额和成长分析（按治疗类型、药物类型、最终用户和地区划分）—产业预测（2026-2033 年）

全球僵直性脊椎炎治疗市场规模预计在 2024 年达到 33.4 亿美元，从 2025 年的 36 亿美元成长到 2033 年的 65.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 7.8%。

僵直性脊椎炎（AS）在中青年族群的发生率不断上升，是推动市场成长的主要因素。 AS是一种自体免疫疾病，主要涉及脊椎和骶髂关节，若不及时治疗，可导致严重的疼痛和功能障碍。遗传易感性，例如HLA-B27基因，是造成不同地区发病率差异的主要原因，尤其是在欧洲、北美和亚洲部分地区。随着人们对该疾病认识的提高和诊断技术的改进，AS的早期发现率显着增加，需要长期有效治疗的患者数量也随之增加。生技药品，特别是肿瘤坏死因子（TNF）抑制剂和白细胞介素-17（IL-17）抑制剂，已被证实是靶向发炎路径的有效治疗方法。下一代生技药品的研究进展可望拓展治疗选择，进一步推动投资，并凸显生技药品在市场中的重要性。

推动全球僵直性脊椎炎治疗市场发展的因素

僵直性脊椎炎在全球的发病率不断上升，尤其是在年轻族群中，这显着推动了该市场的扩张。确诊病例的增加带动了对有效治疗方案的需求。为此，医疗机构和製药公司正加大投入，致力于研发创新药物、先进诊断工具和综合患者照护方案。这种持续改进治疗方案的努力，反映了应对僵直性脊椎炎带来的不断变化的医疗挑战的迫切需要，最终将推动市场成长，并有助于改善患者的治疗效果。

限制全球僵直性脊椎炎治疗市场的因素

全球僵直性脊椎炎治疗市场面临许多挑战，尤其是在新兴地区。患者和全科医生对该疾病的认知不足导致诊断延误，这往往会加速疾病进展并降低治疗效果。此外，合格风湿症医师的短缺以及缺乏全面的早期筛检措施，加剧了这些问题。因此，这些因素共同阻碍了市场整体成长，必须克服这些障碍，才能改善患者预后并提高僵直性脊椎炎的治疗效果。

僵直性脊椎炎治疗市场的全球趋势

全球僵直性脊椎炎治疗市场正经历着向生技药品的重大转变，TNF抑制剂和IL-17抑制剂等创新治疗方法正在改变治疗策略。这一转变的特点是，医疗服务提供者和患者越来越倾向于选择这些标靶治疗，因为它们具有更高的疗效和更长期的疾病控制能力。蓬勃发展的研发环境以及不断扩大的生物相似药产品组合进一步推动了市场成长。患者有望获得更好的生活品质和治疗效果，生技药品很可能成为未来僵直性脊椎炎治疗模式的基础。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术分析

全球僵直性脊椎炎治疗市场规模（依治疗类型划分）及复合年增长率（2026-2033 年）

• 非类固醇消炎剂（NSAIDs）
• 生技药品（TNF抑制剂、IL-17抑制剂）
• DMARDs（缓解疾病抗风湿药物）
• 物理治疗/运动疗法
• 其他的

全球僵直性脊椎炎治疗市场规模（按药物类型和复合年增长率划分）（2026-2033 年）

• 原药
• 学名药

全球僵直性脊椎炎治疗市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 专科诊所
• 居家照护

全球僵直性脊椎炎治疗市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• AbbVie Inc.（US）
• Novartis AG（Switzerland）
• Johnson & Johnson（US）
• Pfizer Inc.（US）
• Amgen Inc.（US）
• UCB SA（Belgium）
• Bristol-Myers Squibb（US）
• Eli Lilly and Company（US）
• Roche Holding AG（Switzerland）
• Merck & Co., Inc.（US）
• Biogen Inc.（US）
• Celgene Corporation（US）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Regeneron Pharmaceuticals（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Sandoz International GmbH（Switzerland）
• Lupin Limited（India）
• Mylan NV（US）

结论与建议

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.34 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 6.57 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The rising incidence of ankylosing spondylitis (AS) among young and middle-aged adults is significantly propelling market growth. AS, an autoimmune condition primarily affecting the spine and sacroiliac joints, can lead to debilitating pain and disability if untreated. Genetic predispositions, such as the HLA-B27 gene, contribute to varying incidence rates across regions, particularly in Europe, North America, and parts of Asia. Enhanced awareness and improved diagnostic procedures are facilitating earlier detection, increasing the patient population that requires effective long-term management. Biologic therapies, particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers, have emerged as effective treatments, specifically targeting inflammatory pathways. Ongoing research into next-generation biologics promises to expand treatment options, further driving investment and emphasizing the role of biologics in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Treatment Market Segments Analysis

Global Ankylosing Spondylitis Treatment Market is segmented by Treatment Type, Drug Type, End-User and region. Based on Treatment Type, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Biologics (TNF Inhibitors, IL-17 Inhibitors), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Physical Therapy & Exercise and Others. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on End-User, the market is segmented into Hospitals & Clinics, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Treatment Market

The rising global incidence of ankylosing spondylitis, especially among younger individuals, significantly contributes to the expansion of this market. As the number of diagnosed cases continues to grow, there is an escalating demand for effective treatment options. In response, healthcare providers and pharmaceutical companies are ramping up investments in the development of innovative drugs, advanced diagnostic tools, and comprehensive patient care approaches. This sustained focus on enhancing therapeutic solutions reflects the urgent need to meet the evolving healthcare challenges posed by ankylosing spondylitis, ultimately driving market growth and fostering improved patient outcomes.

Restraints in the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market faces significant challenges, particularly in emerging regions, where limited awareness among patients and general practitioners contributes to delayed diagnoses. This lag in detection often leads to advanced disease progression and diminished treatment efficacy. Furthermore, a shortage of qualified rheumatologists, coupled with the lack of comprehensive initial screening initiatives, exacerbates these issues. As a result, these factors collectively hinder overall market growth, creating obstacles that must be addressed to improve patient outcomes and enhance the effectiveness of ankylosing spondylitis management.

Market Trends of the Global Ankylosing Spondylitis Treatment Market

The global ankylosing spondylitis treatment market is witnessing a significant shift towards biologics, with innovative therapies like TNF and IL-17 inhibitors transforming management strategies. This evolution is characterized by a growing preference among healthcare providers and patients for these targeted therapies, which offer improved efficacy and long-term disease control. The robust research and development landscape, coupled with an expanding portfolio of biosimilars, is further propelling market growth. Patients can expect enhanced quality of life and better therapeutic outcomes, positioning biologics as the cornerstone of future treatment paradigms in ankylosing spondylitis care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Ankylosing Spondylitis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Biologics (TNF Inhibitors, IL-17 Inhibitors)
• DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
• Physical Therapy & Exercise
• Others

Global Ankylosing Spondylitis Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Branded Drugs
• Generic Drugs

Global Ankylosing Spondylitis Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Specialty Clinics
• Home Care

Global Ankylosing Spondylitis Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Type, End-User)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations